It was founded in 2005 and Key employees including CEO and directors have a cumulative experience in the biopharmaceutical field. BiocurePharm has already experiences to developed several recombinant biosimilars such as Interferon-β, Filgrastim, EPO, Ranibizumab, and Enbrel. Based on such achievements, BiocurePharm started to develop the immunocell therapy, CAR-T cell therapy, with Pharosvacine in 2016. And non-clinical study completed in 2018 and IND submitted for clinical study for relapse and refractory acute lymphoblastic leukemia.
Biocure Pharm
Category:
Venture
Main Business Area
BiocurePharm is a biopharmaceutical company comprised of leading scientists specializing in the development and commercialization of major biosimilar products.
| Contact Details | S212, 11-3 Techno 1ro(Gwanqyeong-dong 1337), Yuseong-go, Deajeon 82-42-381-5902biocure@biocure.co.kr |
|---|
Find out more companies
Related products
-
-
-
VentureAprogen
Their main modalities include SDR-Grafting, Recombinant Protein Fusion, CHIMPS Bispecific Antibodies, SHOCAP Bispecific Antibodies, and Bitargeting Receptor-Antibody Hybrid
-
-
